SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. You have free access to this content1
    Robert A. Smith, Deana Manassaram-Baptiste, Durado Brooks, Mary Doroshenk, Stacey Fedewa, Debbie Saslow, Otis W. Brawley, Richard Wender, Cancer screening in the United States, 2015: A review of current American Cancer Society guidelines and current issues in cancer screening, CA: A Cancer Journal for Clinicians, 2015, 65, 1
  2. 2
    Géraldine Pignot, Laurent Salomon, Cédric Lebacle, Yann Neuzillet, Pierre Lunardi, Pascal Rischmann, Marc Zerbib, Cecile Champy, Morgan Roupret, Benoit Peyronnet, Gregory Verhoest, Thibault Murez, Herve Quintens, Stéphane Larré, Nadine Houédé, Eva Compérat, Michel Soulié, Christian Pfister, Prostate cancer incidence on cystoprostatectomy specimens is directly linked to age: results from a multicentre study, BJU International, 2015, 115, 1
  3. 3
    Kosj Yamoah, Curtiland Deville, Neha Vapiwala, Elaine Spangler, Charnita M. Zeigler-Johnson, Bruce Malkowicz, David I. Lee, Michael Kattan, Adam P. Dicker, Timothy R. Rebbeck, African American men with low-grade prostate cancer have increased disease recurrence after prostatectomy compared with Caucasian men11This work was funded in part by PHS, USA, Grant no. R01-CA085074, P50-CA105641, and P60-MD-006900 (to T.R.R.), DOD, USA, Grant no. PC-121189, and the Prostate Cancer Foundation Young Investigator Award (to K.Y.)., Urologic Oncology: Seminars and Original Investigations, 2014,

    CrossRef

  4. 4
    Rodolfo Montironi, Marina Scarpelli, Roberta Mazzucchelli, Antonio Lopez-Beltran, Matteo Santoni, Alberto Briganti, Francesco Montorsi, Liang Cheng, Does prostate acinar adenocarcinoma with Gleason Score 3 + 3 = 6 have the potential to metastasize?, Diagnostic Pathology, 2014, 9, 1, 190

    CrossRef

  5. 5
    Chad G. Rusthoven, Timothy V. Waxweiler, Peter E. DeWitt, Thomas W. Flaig, David Raben, Brian D. Kavanagh, Gleason stratifications prognostic for survival in men receiving definitive external beam radiation therapy for localized prostate cancer, Urologic Oncology: Seminars and Original Investigations, 2014,

    CrossRef

  6. 6
    V. Giannini, A. Vignati, S. Mirasole, S. Mazzetti, F. Russo, M. Stasi, D. Regge, MR-T2-weighted signal intensity: a new imaging biomarker of prostate cancer aggressiveness, Computer Methods in Biomechanics and Biomedical Engineering: Imaging & Visualization, 2014, 1

    CrossRef

  7. 7
    David M. Berman, Jonathan I. Epstein, When is Prostate Cancer Really Cancer?, Urologic Clinics of North America, 2014, 41, 2, 339

    CrossRef

  8. 8
    L. Dickinson, H.U. Ahmed, A.P. Kirkham, C. Allen, A. Freeman, J. Barber, R.G. Hindley, T. Leslie, C. Ogden, R. Persad, M.H. Winkler, M. Emberton, A multi-centre prospective development study evaluating focal therapy using high intensity focused ultrasound for localised prostate cancer: The INDEX study, Contemporary Clinical Trials, 2013, 36, 1, 68

    CrossRef

  9. 9
    Laurence Klotz, Active Surveillance for Prostate Cancer: Overview and Update, Current Treatment Options in Oncology, 2013, 14, 1, 97

    CrossRef

  10. 10
    Richard J. Wassersug, Anthony Lyons, Duane Duncan, Gary W. Dowsett, Marian Pitts, Diagnostic and Outcome Differences Between Heterosexual and Nonheterosexual Men Treated for Prostate Cancer, Urology, 2013, 82, 3, 565

    CrossRef

  11. 11
    Ola Bratt, Stefan Carlsson, Erik Holmberg, Lars Holmberg, Eva Johansson, Andreas Josefsson, Annika Nilsson, Maria Nyberg, David Robinsson, Jonas Sandberg, Dag Sandblom, Pär Stattin, The Study of Active Monitoring in Sweden (SAMS): A randomized study comparing two different follow-up schedules for active surveillance of low-risk prostate cancer, Scandinavian Journal of Urology, 2013, 47, 5, 347

    CrossRef

  12. 12
    Hashim Uddin Ahmed, Manit Arya, Alex Freeman, Mark Emberton, Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?, The Lancet Oncology, 2012, 13, 11, e509

    CrossRef